NCT05112913View on ClinicalTrials.gov

Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

2,520

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

November 19, 2021

Study Completion Date

December 25, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1

600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Trial Locations (1)

710054

Yaliang county Center for Disease Control and Prevention, Xi’an

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY